---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021381"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:32:52.604757+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience Q1 FYARRO sales $5.4M; PRECISION1 fully enrolled; net loss $18.3M

## Summary
- FYARRO net sales $5.4M, down 8.8% YoY due to distributor ordering and fewer patient initiations.
- Net loss $18.3M vs $15.2M in Q1 2023; cash $88.3M expected to fund operations into Q4 2025.
- PRECISION1 trial fully enrolled; two-thirds interim analysis expected Q3 2024, full data early 2025.
- Terminated Mirati/BMS collaboration for adagrasib combo; prioritizing Phase 2 trials in EEC and NETs.
- Management expects return to sales growth in Q2 2024.

## SEC filing metadata
- accession: 0001628280-24-021381
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828024021381/0001628280-24-021381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828024021381/aadi-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021381
- JSON: https://secwatch.observer/filing/0001628280-24-021381.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021381.txt

## Key facts
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $5.4 million, net income $18.3 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $5.4 million
  - Net income: $18.3 million
  - Result: reported results
  source text: for the First Quarter 2024 and Provides Corporate Update Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828024021381/0001628280-24-021381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.